Multicenter, postoperative, randomized controlled, open label, phase II clinical trial of recombinant human endostatin on vascular normalization for esophageal squamous cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Endostatin (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Jul 2015 New trial record
- 02 Jun 2015 Primary endpoint has been met. (overall survival), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.